Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$33.85
-0.9%
$34.87
$29.25
$170.47
$13.09B1.866.66 million shs6.94 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
+4.62%-1.56%-3.83%-15.15%-67.59%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.1053 of 5 stars
4.01.00.04.61.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0074.30% Upside

Current Analyst Ratings Breakdown

Latest MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
2/11/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$41.00 ➝ $34.00
1/29/2025
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$99.00 ➝ $51.00
1/28/2025
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$112.00 ➝ $99.00
(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B4.09N/AN/A$28.33 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable

Recent News About These Companies

JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $33.00
Moderna price target lowered to $33 from $40 at JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna stock logo

Moderna NASDAQ:MRNA

$33.85 -0.32 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$33.95 +0.10 (+0.30%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.